Pioglitazone companion diagnostic - Takeda/Zinfandel

Drug Profile

Pioglitazone companion diagnostic - Takeda/Zinfandel

Alternative Names: AD4833/TOMM40

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda; Zinfandel Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 06 Sep 2017 Phase III development is ongoing for Alzheimer's disease (Diagnosis) in USA, Australia and United Kingdom (NCT02284906)
  • 01 Feb 2015 Takeda initiates a phase III extension trial for Alzheimer's disease (diagnosis) in patients who have completed TOMORROW in USA and United kingdom (NCT02284906)
  • 01 Feb 2015 Phase-III clinical trials in Alzheimer's disease (Diagnosis) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top